Angela Bowman

CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.

Angela Bowman, Hani Gabra, Simon P. Langdon et al. · PubMed · 2002 · 153 citations

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

Charlotte van Kesteren, Chris Twelves, Angela Bowman et al. · Anti-Cancer Drugs · 2002 · 44 citations

Pharmaceutical Science, 3-H Infusion, Pharmacotherapy +16

Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial

Janet E. Brown, Emma Rathbone, Samantha Hinsley et al. · JNCI Journal of the National Cancer Institute · 2017 · 43 citations · Full text

Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors

Miguel Izquierdo, Angela Bowman, Margarita García et al. · Clinical Cancer Research · 2008 · 40 citations

Dose Dense Schedule, Oncology, Solid Tumors +12

Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic–radiation therapy: is a prophylactic feeding tube approach harmful or helpful?

Robert Olson, Irene Karam, Gavin Wilson et al. · Supportive Care in Cancer · 2013 · 37 citations

Population-based Comparison, Radiation Medicine, Radiation Therapy +12